What is the current valuation of the US pain management market?

The US pain management market was valued at $17.5 Billion in 2024. Read More

What is the projected market valuation for the US pain management market by 2035?

The market is projected to reach $31.0 Billion by 2035. Read More

What is the expected CAGR for the US pain management market during the forecast period 2025 - 2035?

The expected CAGR for the market during 2025 - 2035 is 5.34%. Read More

Which segment of pain management had the highest valuation in 2024?

Chronic pain had the highest valuation at $7.0 Billion in 2024. Read More

What are the projected valuations for acute pain in 2035?

The projected valuation for acute pain is $6.0 Billion by 2035. Read More

Which treatment type is expected to grow the most in the US pain management market?

Medication is expected to grow the most, with a projected valuation of $12.0 Billion by 2035. Read More

What is the expected valuation for rehabilitation centers in 2035?

Rehabilitation centers are projected to reach a valuation of $9.55 Billion by 2035. Read More

Which route of administration is anticipated to have the highest valuation in 2035?

The injectable route is anticipated to have the highest valuation at $7.0 Billion by 2035. Read More

Who are the key players in the US pain management market?

Key players include Johnson & Johnson, Pfizer Inc., and AbbVie Inc. Read More

What is the projected valuation for homecare settings in 2035?

Homecare settings are projected to reach a valuation of $5.0 Billion by 2035. Read More

US Pain Management Market

ID: MRFR/MED/12040-HCR

100 Pages

Nidhi Mandole

Last Updated: April 06, 2026

United States Pain Management Market Research Report: Size, Share, Trend Analysis - Growth Outlook & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Pharmaceutical, BY Type of Pain (USD Billion)
  1. 4.1.1 Acute Pain
  2. 4.1.2 Chronic Pain
  3. 4.1.3 Neuropathic Pain
  4. 4.1.4 Nociceptive Pain
2. 4.2 Pharmaceutical, BY Treatment Type (USD Billion)
  1. 4.2.1 Medication
  2. 4.2.2 Physical Therapy
  3. 4.2.3 Interventional Procedures
  4. 4.2.4 Alternative Therapies
3. 4.3 Pharmaceutical, BY End User (USD Billion)
  1. 4.3.1 Hospitals
  2. 4.3.2 Clinics
  3. 4.3.3 Homecare Settings
  4. 4.3.4 Rehabilitation Centers
4. 4.4 Pharmaceutical, BY Route of Administration (USD Billion)
  1. 4.4.1 Oral
  2. 4.4.2 Topical
  3. 4.4.3 Injectable
  4. 4.4.4 Transdermal
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Pharmaceutical
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Johnson & Johnson (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Pfizer Inc. (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 AbbVie Inc. (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Boehringer Ingelheim (DE)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Amgen Inc. (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Eli Lilly and Company (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Teva Pharmaceutical Industries Ltd. (IL)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Mylan N.V. (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Novartis AG (CH)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TYPE OF PAIN
3. 6.3 US MARKET ANALYSIS BY TREATMENT TYPE
4. 6.4 US MARKET ANALYSIS BY END USER
5. 6.5 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6. 6.6 KEY BUYING CRITERIA OF PHARMACEUTICAL
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF PHARMACEUTICAL
9. 6.9 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
10. 6.10 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
11. 6.11 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
12. 6.12 PHARMACEUTICAL, BY TYPE OF PAIN, 2024 (% SHARE)
13. 6.13 PHARMACEUTICAL, BY TYPE OF PAIN, 2024 TO 2035 (USD Billion)
14. 6.14 PHARMACEUTICAL, BY TREATMENT TYPE, 2024 (% SHARE)
15. 6.15 PHARMACEUTICAL, BY TREATMENT TYPE, 2024 TO 2035 (USD Billion)
16. 6.16 PHARMACEUTICAL, BY END USER, 2024 (% SHARE)
17. 6.17 PHARMACEUTICAL, BY END USER, 2024 TO 2035 (USD Billion)
18. 6.18 PHARMACEUTICAL, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
19. 6.19 PHARMACEUTICAL, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE OF PAIN, 2025-2035 (USD Billion)
  2. 7.2.2 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  3. 7.2.3 BY END USER, 2025-2035 (USD Billion)
  4. 7.2.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Pharmaceutical Market Segmentation

Pharmaceutical By Type of Pain (USD Billion, 2025-2035)

Acute Pain
Chronic Pain
Neuropathic Pain
Nociceptive Pain

Pharmaceutical By Treatment Type (USD Billion, 2025-2035)

Medication
Physical Therapy
Interventional Procedures
Alternative Therapies

Pharmaceutical By End User (USD Billion, 2025-2035)

Hospitals
Clinics
Homecare Settings
Rehabilitation Centers

Pharmaceutical By Route of Administration (USD Billion, 2025-2035)

Oral
Topical
Injectable
Transdermal

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”